Guidance for Industry on Providing Regulatory Submissions in Electronic Format-Receipt Date; Correction, 11449 [2014-04424]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 40 / Friday, February 28, 2014 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2007–D–0077 (Formerly
2007D–0213)]
Guidance for Industry on Providing
Regulatory Submissions in Electronic
Format—Receipt Date; Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug
Administration (FDA) is correcting a
notice that appeared in the Federal
Register of Friday, February 7, 2014 (79
FR 7463). The document announced the
availability of a guidance entitled
‘‘Providing Regulatory Submissions in
Electronic Format—Receipt Date.’’ The
document was published with an
incorrect Web site in the ‘‘Electronic
Access’’ section. This document corrects
that error.
FOR FURTHER INFORMATION CONTACT:
Marina Kalinina, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, rm. 1183,
Silver Spring, MD 20993, 301–796–
7591; or Stephen Ripley, Center for
Biologics Evaluation and Research,
Food and Drug Administration, 5515
Security Lane, rm. 5130, Rockville, MD
20852, 301–827–6210.
SUPPLEMENTARY INFORMATION:
In FR Doc. 2014–02654, appearing on
page 7463 in the Federal Register of
Friday, February 7, 2014, the following
correction is made:
1. On page 7464, in the first column,
in the ‘‘Electronic Access’’ section, the
Web site ‘‘https://www.fda.gov/Drugs/
DevelopmentApprovalProcess/Forms
SubmissionRequirements/Electronic
Submissions/ucm253101.htm’’ is
corrected to read ‘‘https://www.fda.gov/
Drugs/GuidanceComplianceRegulatory
Information/Guidances/default.htm.’’
SUMMARY:
Dated: February 25, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–04424 Filed 2–27–14; 8:45 am]
BILLING CODE 4160–01–P
tkelley on DSK3SPTVN1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Social Sciences and
VerDate Mar<15>2010
17:47 Feb 27, 2014
Jkt 232001
Population Studies B Study Section,
February 28, 2014, 08:00 a.m. to
February 28, 2014, 05:00 p.m.,
Renaissance Long Beach Hotel, 111 East
Ocean Blvd., Long Beach, CA, 90802
which was published in the Federal
Register on February 18, 2014, 79 FR
9243.
The meeting will be held at the
Courtyard Long Beach Downtown, 500
East 1st Street, Long Beach, CA 90802.
The meeting date and time remain the
same. The meeting is closed to the
public.
Dated: February 24, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–04363 Filed 2–27–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Integrating Substance Abuse Prevention and
Treatment within HIV/AIDS Service Delivery
Settings.
Date: March 20, 2014.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Eliane Lazar-Wesley,
Ph.D., Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Blvd., Room 4245, MSC 9550, Bethesda, MD
20892–9550, 301–451–4530, el6r@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
11449
Dated: February 21, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–04369 Filed 2–27–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, NIAID Peer Review Meeting.
Date: March 11, 2014.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, Room
3201 B, 6700B Rockledge Drive, Bethesda,
MD 20817, (Telephone Conference Call).
Contact Person: Travis J Taylor, Ph.D.,
Scientific Review Program, DEA/NIAID/NIH/
DHHS, 6700–B Rockledge Dr. MSC–7616,
Bethesda, MD 20892–7616, 301–496–2550,
Travis.Taylor@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, ‘‘NIAID Clinical Trial
Planning Grants (R34) and Implementation
Grants and Cooperative Agreements (U01)’’.
Date: March 21, 2014.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3122, 6700B Rockledge Drive, Bethesda, MD
20817, (Telephone Conference Call).
Contact Person: Brenda Lange-Gustafson,
Ph.D., Scientific Review Officer, NIAID/NIH/
DHHS, Scientific Review Program, Room
3122, 6700–B Rockledge Drive, MSC–7616,
Bethesda, MD 20892–7616, 301–451–3684,
bgustafson@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
E:\FR\FM\28FEN1.SGM
28FEN1
]]>Agencies
[Federal Register Volume 79, Number 40 (Friday, February 28, 2014)]
[Notices]
[Page 11449]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-04424]
[[Page 11449]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2007-D-0077 (Formerly 2007D-0213)]
Guidance for Industry on Providing Regulatory Submissions in
Electronic Format--Receipt Date; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
that appeared in the Federal Register of Friday, February 7, 2014 (79
FR 7463). The document announced the availability of a guidance
entitled ``Providing Regulatory Submissions in Electronic Format--
Receipt Date.'' The document was published with an incorrect Web site
in the ``Electronic Access'' section. This document corrects that
error.
FOR FURTHER INFORMATION CONTACT: Marina Kalinina, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, rm. 1183, Silver Spring, MD 20993, 301-796-
7591; or Stephen Ripley, Center for Biologics Evaluation and Research,
Food and Drug Administration, 5515 Security Lane, rm. 5130, Rockville,
MD 20852, 301-827-6210.
SUPPLEMENTARY INFORMATION:
In FR Doc. 2014-02654, appearing on page 7463 in the Federal
Register of Friday, February 7, 2014, the following correction is made:
1. On page 7464, in the first column, in the ``Electronic Access''
section, the Web site ``https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/ucm253101.htm'' is corrected to read ``https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.''
Dated: February 25, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-04424 Filed 2-27-14; 8:45 am]
BILLING CODE 4160-01-P
